LASSBio-1135

LASSBio-1135

• CAS Number: 852453-71-5
• UNSPSC Description: LASSBio-1135 (Compound 3a) is an orally active TRPV1 antagonist. LASSBio-1135 is an anti-inflammatory and analgesic compound. LASSBio-1135 inhibits moderately the human PGHS-2 enzyme activity (IC50 = 18.5 μM). LASSBio-1135 reverts the Capsaicin (HY-10448)-induced thermal hyperalgesia and reduces the carrageenan-induced rat paw edem[1].
• Target Antigen: TRP Channel
• Type: Reference compound
• Related Pathways: Membrane Transporter/Ion Channel;Neuronal Signaling
• Field of Research: Inflammation/Immunology; Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/lassbio-1135.html
• Purity: 99.05
• Solubility: DMSO : 6.67 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: C12=NC(C3=NC=CC=C3)=C(NC4=CC=CC=C4)N1C=CC=C2
• Molecular Weight: 286.33
• References & Citations: [1]Lacerda RB, et al. Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorg Med Chem. 2009 Jan 1;17(1):74-84.|[2]Lima CK, et al. LASSBio-1135: a dual TRPV1 antagonist and anti-TNF-alpha compound orally effective in models of inflammatory and neuropathic pain. PLoS One. 2014 Jun 18;9(6):e99510.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported